STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Announcements

Filter Results

All Price Sensitive Only

SPL	Starpharma receives $7.2 million R&D Tax Incentive refund	PRICE SENSITIVE	23/10/23	195.31KB	Share
SPL	Ceasing to be a substantial holder		23/10/23	382.58KB	Share
SPL	Change in substantial holding		20/10/23	178.85KB	Share
SPL	Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer	PRICE SENSITIVE	18/10/23	386.76KB	Share
SPL	DEP irinotecan IO/PARP combination data presented at AACR		16/10/23	508.19KB	Share
SPL	DEP theranostic presented at international oncology meeting		16/10/23	683.45KB	Share
SPL	DEP irinotecan clinical data presented at AACR meeting	PRICE SENSITIVE	16/10/23	1.59MB	Share
SPL	Ceasing to be a substantial holder		16/10/23	115.13KB	Share
SPL	Application for quotation of securities - SPL		09/10/23	26.19KB	Share
SPL	Change in Director's Interest Notice - J Fairley		06/10/23	297.01KB	Share
SPL	Notification of cessation of securities - SPL		06/10/23	21.61KB	Share
SPL	2023 Annual General Meeting Date		02/10/23	212.03KB	Share
SPL	Ceasing to be a substantial holder		29/09/23	188.92KB	Share
SPL	DEP irinotecan combination data presentation	PRICE SENSITIVE	27/09/23	244.62KB	Share
SPL	VIRALEZ UK COVID-19 Clinical Study Completes Recruitment	PRICE SENSITIVE	25/09/23	211KB	Share
SPL	Change in substantial holding		20/09/23	685.22KB	Share
SPL	Positive DEP irinotecan clinical results presentation	PRICE SENSITIVE	13/09/23	305.62KB	Share
SPL	Change in substantial holding		12/09/23	181.87KB	Share
SPL	Company Secretary Appointment/Resignation		28/08/23	211.6KB	Share
SPL	Corporate Governance Statement		25/08/23	620.78KB	Share
SPL	Appendix 4G - Corporate Governance Statement		24/08/23	390.09KB	Share
SPL	App 4E/Annual Report to shareholders	PRICE SENSITIVE	24/08/23	4.53MB	Share
SPL	Change in substantial holding		17/08/23	331KB	Share
SPL	Change in substantial holding		17/08/23	183.33KB	Share
SPL	Change in substantial holding		15/08/23	171.85KB	Share
SPL	SPL to receive $6.5M from Mundipharma and VivaGel BV rights	PRICE SENSITIVE	14/08/23	200.3KB	Share
SPL	Change in substantial holding		02/08/23	5.32MB	Share
SPL	Partnered Program Update	PRICE SENSITIVE	31/07/23	217.74KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	731.65KB	Share
SPL	Trading Halt	PRICE SENSITIVE	28/07/23	218.36KB	Share
SPL	Pause in Trading	PRICE SENSITIVE	28/07/23	114.3KB	Share
SPL	Starpharma partners with UQ to advance DEP radio pipeline	PRICE SENSITIVE	26/07/23	216.87KB	Share
SPL	DEP HER2-radiodiagnostic shows imaging benefits	PRICE SENSITIVE	21/07/23	293.92KB	Share
SPL	Notification of cessation of securities - SPL		07/07/23	21.71KB	Share
SPL	Clinical Trial Update	PRICE SENSITIVE	27/06/23	213.03KB	Share
SPL	Life Sciences Investor Forum Presentation		23/06/23	6.12MB	Share
SPL	Starpharma to present at Life Sciences Investor Forum		22/06/23	214.29KB	Share
SPL	AZD0466 Clinical Data Presented by AstraZeneca EHA Congress		14/06/23	774.67KB	Share
SPL	Starpharma CEO to retire in 2024	PRICE SENSITIVE	09/06/23	178.72KB	Share
SPL	VIRALEZE Nasal Spray Approved in Malaysia	PRICE SENSITIVE	05/06/23	225.85KB	Share
SPL	Application for quotation of securities - SPL		05/05/23	26.53KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	401.33KB	Share
SPL	HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model	PRICE SENSITIVE	26/04/23	302.96KB	Share
SPL	AZD0466 active in small cell lung cancer patient models		20/04/23	3.03MB	Share
SPL	DEP cabazitaxel Ph 2 trial completes enrolment & treatment		17/04/23	232.51KB	Share
SPL	Commencement of CFO and Company Secretary		03/04/23	288.56KB	Share
SPL	Starpharma presents at ASX Small and Mid-Cap Conference		22/03/23	6.82MB	Share
SPL	Application for quotation of securities - SPL		17/03/23	26.19KB	Share
SPL	CFO and Company Secretary Appointment		03/03/23	200.63KB	Share
SPL	Interim Report and Half-Year Financial Results	PRICE SENSITIVE	28/02/23	1.2MB	Share
SPL	Dr Russell Basser appointed as director and Appendix 3X		20/02/23	374.97KB	Share
SPL	Change in substantial holding		10/02/23	187.43KB	Share
SPL	Change in substantial holding		10/02/23	190.19KB	Share
SPL	Application for quotation of securities - SPL		01/02/23	26.48KB	Share
SPL	Appointment of Company Secretary		01/02/23	192.34KB	Share
SPL	Dr Russell Basser appointed as non-executive director		31/01/23	220.08KB	Share
SPL	Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	30/01/23	329.34KB	Share
SPL	Response to ASX Query Letters	PRICE SENSITIVE	12/01/23	504.84KB	Share
SPL	Starpharma receives $7.1M R&D tax incentive refund	PRICE SENSITIVE	23/12/22	200.28KB	Share
SPL	Resignation of CFO / Company Secretary		21/12/22	207KB	Share
SPL	VIRALEZE Nasal Spray Registered in Indonesia	PRICE SENSITIVE	14/12/22	229.62KB	Share
SPL	Positive AZD0466 clinical data presented by AstraZeneca	PRICE SENSITIVE	13/12/22	258.89KB	Share
SPL	VIRALEZE Post-Market Clinical Study in COVID-19 Patients		08/12/22	198.55KB	Share
SPL	Change in Director's Interest Notice - J Fairley		05/12/22	275.72KB	Share
SPL	Notification regarding unquoted securities - SPL		05/12/22	25.23KB	Share
SPL	Retirement of non-executive Director		30/11/22	343.84KB	Share
SPL	AGM Results		29/11/22	222.82KB	Share
SPL	AGM Chairman address and CEO presentation	PRICE SENSITIVE	29/11/22	7.66MB	Share
SPL	VIRALEZE launched in Hong Kong and Macau		21/11/22	217.36KB	Share
SPL	Starpharma to present at Bell Potter Healthcare Conference		08/11/22	7.23MB	Share
SPL	Change in Director's Interest Notice - R Thomas		31/10/22	178.82KB	Share
SPL	Change in Director's Interest Notice - J Fairley		31/10/22	189.72KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		28/10/22	7.16MB	Share
SPL	Application for quotation of securities - SPL		27/10/22	26.54KB	Share
SPL	Notification regarding unquoted securities - SPL		27/10/22	26.28KB	Share
SPL	Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	26/10/22	379.1KB	Share
SPL	VIRALEZE distribution agreement for Hong Kong and Macau	PRICE SENSITIVE	21/10/22	197.81KB	Share
SPL	Change in substantial holding		21/10/22	463.6KB	Share
SPL	Change in Director's Interest Notice - J Fairley		07/10/22	191.19KB	Share
SPL	Notification of cessation of securities - SPL		07/10/22	21.47KB	Share
SPL	Board Renewal		05/10/22	188.87KB	Share
SPL	2022 Annual General Meeting Date		30/09/22	171.84KB	Share
SPL	Starpharma to present at Life Sciences Investor Forum		15/09/22	7.57MB	Share
SPL	Change in substantial holding		12/09/22	225.91KB	Share
SPL	Change in Director's Interest Notice - J Fairley		12/09/22	190.1KB	Share
SPL	New clinical data for DEP cabazitaxel in prostate cancer	PRICE SENSITIVE	12/09/22	307.37KB	Share
SPL	S&P DJI Announces September 2022 Quarterly Rebalance	PRICE SENSITIVE	02/09/22	134KB	Share
SPL	Starpharma annual report and full year financial results	PRICE SENSITIVE	25/08/22	7.93MB	Share
SPL	Appendix 4G - Corporate Governance Statement		25/08/22	401.49KB	Share
SPL	Starpharma signs new DEP agreement with MSD	PRICE SENSITIVE	10/08/22	184.49KB	Share
SPL	Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	29/07/22	363.61KB	Share
SPL	VIRALEZE Protects Against Omicron in Viral Challenge Model	PRICE SENSITIVE	20/07/22	328.62KB	Share
SPL	Change in substantial holding		05/07/22	16.3MB	Share
SPL	VIRALEZE relaunched by LloydsPharmacy in the UK	PRICE SENSITIVE	30/06/22	192.04KB	Share
SPL	SPL signs expanded DEP research agreement with US Biopharma	PRICE SENSITIVE	27/06/22	194.04KB	Share
SPL	Shareholder Newsletter		03/06/22	733.83KB	Share
SPL	Notification of cessation of securities - SPL		27/05/22	21.51KB	Share
SPL	Application for quotation of securities - SPL		27/05/22	26.57KB	Share
SPL	SPL7013 in VIRALEZE virucidal against influenza A and B	PRICE SENSITIVE	18/05/22	281.77KB	Share
SPL	Quarterly Cashflow and Activities Report	PRICE SENSITIVE	29/04/22	357.52KB	Share

SPL Starpharma receives $7.2 million R&D Tax Incentive refund
23/10/23	PRICE SENSITIVE	195.31KB	Share
SPL Ceasing to be a substantial holder
23/10/23		382.58KB	Share
SPL Change in substantial holding
20/10/23		178.85KB	Share
SPL Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
18/10/23	PRICE SENSITIVE	386.76KB	Share
SPL DEP irinotecan IO/PARP combination data presented at AACR
16/10/23		508.19KB	Share
SPL DEP theranostic presented at international oncology meeting
16/10/23		683.45KB	Share
SPL DEP irinotecan clinical data presented at AACR meeting
16/10/23	PRICE SENSITIVE	1.59MB	Share
SPL Ceasing to be a substantial holder
16/10/23		115.13KB	Share
SPL Application for quotation of securities - SPL
09/10/23		26.19KB	Share
SPL Change in Director's Interest Notice - J Fairley
06/10/23		297.01KB	Share
SPL Notification of cessation of securities - SPL
06/10/23		21.61KB	Share
SPL 2023 Annual General Meeting Date
02/10/23		212.03KB	Share
SPL Ceasing to be a substantial holder
29/09/23		188.92KB	Share
SPL DEP irinotecan combination data presentation
27/09/23	PRICE SENSITIVE	244.62KB	Share
SPL VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
25/09/23	PRICE SENSITIVE	211KB	Share
SPL Change in substantial holding
20/09/23		685.22KB	Share
SPL Positive DEP irinotecan clinical results presentation
13/09/23	PRICE SENSITIVE	305.62KB	Share
SPL Change in substantial holding
12/09/23		181.87KB	Share
SPL Company Secretary Appointment/Resignation
28/08/23		211.6KB	Share
SPL Corporate Governance Statement
25/08/23		620.78KB	Share
SPL Appendix 4G - Corporate Governance Statement
24/08/23		390.09KB	Share
SPL App 4E/Annual Report to shareholders
24/08/23	PRICE SENSITIVE	4.53MB	Share
SPL Change in substantial holding
17/08/23		331KB	Share
SPL Change in substantial holding
17/08/23		183.33KB	Share
SPL Change in substantial holding
15/08/23		171.85KB	Share
SPL SPL to receive $6.5M from Mundipharma and VivaGel BV rights
14/08/23	PRICE SENSITIVE	200.3KB	Share
SPL Change in substantial holding
02/08/23		5.32MB	Share
SPL Partnered Program Update
31/07/23	PRICE SENSITIVE	217.74KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	731.65KB	Share
SPL Trading Halt
28/07/23	PRICE SENSITIVE	218.36KB	Share
SPL Pause in Trading
28/07/23	PRICE SENSITIVE	114.3KB	Share
SPL Starpharma partners with UQ to advance DEP radio pipeline
26/07/23	PRICE SENSITIVE	216.87KB	Share
SPL DEP HER2-radiodiagnostic shows imaging benefits
21/07/23	PRICE SENSITIVE	293.92KB	Share
SPL Notification of cessation of securities - SPL
07/07/23		21.71KB	Share
SPL Clinical Trial Update
27/06/23	PRICE SENSITIVE	213.03KB	Share
SPL Life Sciences Investor Forum Presentation
23/06/23		6.12MB	Share
SPL Starpharma to present at Life Sciences Investor Forum
22/06/23		214.29KB	Share
SPL AZD0466 Clinical Data Presented by AstraZeneca EHA Congress
14/06/23		774.67KB	Share
SPL Starpharma CEO to retire in 2024
09/06/23	PRICE SENSITIVE	178.72KB	Share
SPL VIRALEZE Nasal Spray Approved in Malaysia
05/06/23	PRICE SENSITIVE	225.85KB	Share
SPL Application for quotation of securities - SPL
05/05/23		26.53KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	401.33KB	Share
SPL HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model
26/04/23	PRICE SENSITIVE	302.96KB	Share
SPL AZD0466 active in small cell lung cancer patient models
20/04/23		3.03MB	Share
SPL DEP cabazitaxel Ph 2 trial completes enrolment & treatment
17/04/23		232.51KB	Share
SPL Commencement of CFO and Company Secretary
03/04/23		288.56KB	Share
SPL Starpharma presents at ASX Small and Mid-Cap Conference
22/03/23		6.82MB	Share
SPL Application for quotation of securities - SPL
17/03/23		26.19KB	Share
SPL CFO and Company Secretary Appointment
03/03/23		200.63KB	Share
SPL Interim Report and Half-Year Financial Results
28/02/23	PRICE SENSITIVE	1.2MB	Share
SPL Dr Russell Basser appointed as director and Appendix 3X
20/02/23		374.97KB	Share
SPL Change in substantial holding
10/02/23		187.43KB	Share
SPL Change in substantial holding
10/02/23		190.19KB	Share
SPL Application for quotation of securities - SPL
01/02/23		26.48KB	Share
SPL Appointment of Company Secretary
01/02/23		192.34KB	Share
SPL Dr Russell Basser appointed as non-executive director
31/01/23		220.08KB	Share
SPL Quarterly Activities Report & Appendix 4C
30/01/23	PRICE SENSITIVE	329.34KB	Share
SPL Response to ASX Query Letters
12/01/23	PRICE SENSITIVE	504.84KB	Share
SPL Starpharma receives $7.1M R&D tax incentive refund
23/12/22	PRICE SENSITIVE	200.28KB	Share
SPL Resignation of CFO / Company Secretary
21/12/22		207KB	Share
SPL VIRALEZE Nasal Spray Registered in Indonesia
14/12/22	PRICE SENSITIVE	229.62KB	Share
SPL Positive AZD0466 clinical data presented by AstraZeneca
13/12/22	PRICE SENSITIVE	258.89KB	Share
SPL VIRALEZE Post-Market Clinical Study in COVID-19 Patients
08/12/22		198.55KB	Share
SPL Change in Director's Interest Notice - J Fairley
05/12/22		275.72KB	Share
SPL Notification regarding unquoted securities - SPL
05/12/22		25.23KB	Share
SPL Retirement of non-executive Director
30/11/22		343.84KB	Share
SPL AGM Results
29/11/22		222.82KB	Share
SPL AGM Chairman address and CEO presentation
29/11/22	PRICE SENSITIVE	7.66MB	Share
SPL VIRALEZE launched in Hong Kong and Macau
21/11/22		217.36KB	Share
SPL Starpharma to present at Bell Potter Healthcare Conference
08/11/22		7.23MB	Share
SPL Change in Director's Interest Notice - R Thomas
31/10/22		178.82KB	Share
SPL Change in Director's Interest Notice - J Fairley
31/10/22		189.72KB	Share
SPL Notice of Annual General Meeting/Proxy Form
28/10/22		7.16MB	Share
SPL Application for quotation of securities - SPL
27/10/22		26.54KB	Share
SPL Notification regarding unquoted securities - SPL
27/10/22		26.28KB	Share
SPL Quarterly Activities Report & Appendix 4C
26/10/22	PRICE SENSITIVE	379.1KB	Share
SPL VIRALEZE distribution agreement for Hong Kong and Macau
21/10/22	PRICE SENSITIVE	197.81KB	Share
SPL Change in substantial holding
21/10/22		463.6KB	Share
SPL Change in Director's Interest Notice - J Fairley
07/10/22		191.19KB	Share
SPL Notification of cessation of securities - SPL
07/10/22		21.47KB	Share
SPL Board Renewal
05/10/22		188.87KB	Share
SPL 2022 Annual General Meeting Date
30/09/22		171.84KB	Share
SPL Starpharma to present at Life Sciences Investor Forum
15/09/22		7.57MB	Share
SPL Change in substantial holding
12/09/22		225.91KB	Share
SPL Change in Director's Interest Notice - J Fairley
12/09/22		190.1KB	Share
SPL New clinical data for DEP cabazitaxel in prostate cancer
12/09/22	PRICE SENSITIVE	307.37KB	Share
SPL S&P DJI Announces September 2022 Quarterly Rebalance
02/09/22	PRICE SENSITIVE	134KB	Share
SPL Starpharma annual report and full year financial results
25/08/22	PRICE SENSITIVE	7.93MB	Share
SPL Appendix 4G - Corporate Governance Statement
25/08/22		401.49KB	Share
SPL Starpharma signs new DEP agreement with MSD
10/08/22	PRICE SENSITIVE	184.49KB	Share
SPL Quarterly Activities Report & Appendix 4C
29/07/22	PRICE SENSITIVE	363.61KB	Share
SPL VIRALEZE Protects Against Omicron in Viral Challenge Model
20/07/22	PRICE SENSITIVE	328.62KB	Share
SPL Change in substantial holding
05/07/22		16.3MB	Share
SPL VIRALEZE relaunched by LloydsPharmacy in the UK
30/06/22	PRICE SENSITIVE	192.04KB	Share
SPL SPL signs expanded DEP research agreement with US Biopharma
27/06/22	PRICE SENSITIVE	194.04KB	Share
SPL Shareholder Newsletter
03/06/22		733.83KB	Share
SPL Notification of cessation of securities - SPL
27/05/22		21.51KB	Share
SPL Application for quotation of securities - SPL
27/05/22		26.57KB	Share
SPL SPL7013 in VIRALEZE virucidal against influenza A and B
18/05/22	PRICE SENSITIVE	281.77KB	Share
SPL Quarterly Cashflow and Activities Report
29/04/22	PRICE SENSITIVE	357.52KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$30.60K	232.5K

Buyers (Bids)

No.	Vol.	Price($)
1	458760	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	87374	5

View Market Depth

No.	Vol.	Price($)
1	458760	0.130
2	51308	0.125
1	43350	0.115
2	9099	0.110
2	86433	0.105

Price($)	Vol.	No.
0.135	87374	5
0.140	162743	4
0.145	71840	7
0.150	175000	3
0.155	108518	3

Last trade - 15.09pm 05/09/2025 (20 minute delay)

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories